1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

4506.T
Sumitomo Pharma Co., Ltd.JP flagTokyo Stock Exchange
1,457.00
JPY
-68.00
- -
653.60BMarket Cap
Sumitomo Pharma Co., Ltd.
4506.T
(Tokyo Stock Exchange)

Recent

price

1,457.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
955.24
881.89
875.22
975.84
934.72
1,014.86
1,027.83
1,175.03
1,155.98
1,215.05
1,298.67
1,409.63
1,398.33
791.76
1,003.91
- -
407.53
Revenue per Share
42.27
21.72
25.28
50.49
38.88
62.16
78.82
134.53
122.39
102.58
141.5
141.99
-187.55
-792.79
59.49
- -
-622.25
Basic EPS, GAAP
115.51
99.5
100.4
71.45
45.02
99.86
14.31
204.04
90.1
82.5
314.11
44.66
-2.03
-648.45
8.73
- -
-187.98
Free Cash Flow per Basic Share
17.99
17.99
18
18
18
18
18
20
27.99
32.99
27.99
28
28
7.03
0.01
- -
0.02
Dividend per Share
821.98
769.33
776.61
802.56
822.25
877.82
956.88
1,053.2
1,143.22
1,207.49
1,336.74
1,350.67
763.67
-0.67
174.15
- -
23.02
Book Value per Share
454.85
532.38
510.78
608.46
697.6
588.53
289.35
422.72
572.37
104.12
222.2
200.69
-332.12
-602.33
-504.52
- -
-640.04
Tangible Book Value per Share
397
397
397
397
397
397
397
397
397
397
397
397
397
397
397
- -
397
Basic Weighted Avg Shares
379,529
350,384
347,732
387,709
371,370
403,205
408,357
466,838
459,267
482,732
515,952
560,035
555,544
314,558
398,832
453,294
161,916
Sales/Revenue/Turnover
34.41
5.82
7.2
10.87
6.27
9.16
9.87
18.89
12.6
17.24
13.8
10.76
-13.86
-112.8
7.45
23.18
-165.74
Operating Margin (%)
44,627
40,232
35,085
26,776
19,226
20,265
12,713
12,887
13,976
17,365
22,673
38,348
41,263
37,765
25,562
- -
19,106
Depreciation Expense
16,796
8,629
10,043
20,060
15,447
24,697
31,316
53,448
48,627
40,753
56,219
56,413
-74,512
-314,969
23,634
106,865
-247,228
Net Income, GAAP
32.95
47.15
44.69
42.2
54.23
37.57
26.8
37.02
25.24
57.21
52.69
51.06
- -
- -
- -
- -
- -
Effective Tax Rate (%)
4.43
2.46
2.89
5.17
4.16
6.13
7.67
11.45
10.59
8.44
10.9
10.07
-13.41
-100.13
5.93
23.58
-152.69
Profit Margin (%)
175,796
228,285
208,607
228,404
244,856
157,658
75,427
138,333
175,094
-132,408
181,648
221,148
9,166
-245,905
12,565
7,752
-174,588
Working Capital
93,000
118,000
95,000
85,000
50,000
28,000
10,000
30,940
27,980
25,020
263,859
243,963
244,128
133,367
258,982
179,056
133,430
LT Debt
323,983
319,227
349,248
398,540
451,021
389,594
412,268
452,723
498,138
635,860
648,178
673,569
406,782
156,136
169,479
292,467
114,244
Total Equity
17.46
2.3
3.01
5.02
2.04
4.57
6.15
11.05
8.17
4.74
3.54
3.11
- -
- -
- -
- -
- -
Return on Invested Capital (%)
3.76
2.02
2.48
4.93
3.84
6.22
7.51
12.49
10.26
6.85
8.76
8.45
- -
- -
- -
- -
- -
Return on Capital (%)
5.22
2.73
3.27
6.39
4.79
7.31
8.59
13.39
11.14
8.73
11.12
10.57
-17.74
- -
- -
85.3
-198.6
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
285,517
- -
255,950
LT Borrowings
133,367
- -
133,430
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
397
- -
397
Market Capitalization
158,122
160,908
236,798

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
269,569
- -
311,929
Cash, Cash Equivalents & STI
36,132
- -
115,911
Accounts Receivable, Net
81,023
- -
66,063
Inventories
115,350
- -
105,637
Total Current Liabilities
515,474
- -
486,517
Payables & Accruals
- -
- -
- -
ST Debt
285,517
- -
255,950
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.91%
-3.24%
72.57%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
44.59%
67.13%
352.17%
Sales/Revenue/Turnover
3.08%
0.96%
13.66%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
75,686
76,956
82,386
79,530
314,558
2025
- -
- -
- -
- -
398,832
2026
- -
- -
- -
- -
453,294

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-97.81
-72.68
-125.77
- -
-792.79
2025
- -
- -
- -
- -
59.49
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6.89
0.12
0.02
- -
7.03
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Similar Companies
InterCure Ltd. (INCR.TA)
Planet 13 Holdings Inc. (PLNH)
HLS Therapeutics Inc. (HLS.TO)
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS)
Sequent Scientific Limited (SEQUENT.NS)
Gufic Biosciences Limited (GUFICBIO.BO)
Business
Sumitomo Pharma Co., Ltd. Sumitomo Pharma Co., Ltd. engages primarily in the research, development, manufacture, and sale of pharmaceutical products targeting oncology, psychiatry and neurology, rare diseases, regenerative medicine, and cell therapy; cardiovascular and diabetes treatments; as well as infectious diseases, urological disorders, and women's health issues. The company offers prescription drugs for conditions including Parkinson's disease, depression, type 2 diabetes, hypertension, overactive bladder, chronic obstructive pulmonary disease, systemic fungal infections, pruritus, advanced prostate cancer, uterine fibroids, arrhythmia, and angina pectoris; atypical antipsychotics; antiepileptics; carbapenem antibiotics; Fabry disease therapies; and cultured thymus tissue for pediatric congenital athymia, with additional operations in food ingredients such as polysaccharides and seasonings, veterinary medicines, diagnostic reagents, and chemical materials like pharmaceutical excipients, personal care products, coatings, and electronic materials. Founded on May 14, 1897 and headquartered in Osaka, Japan, with key offices in Tokyo and global presence in North America, China, and other international markets, Sumitomo Pharma operates through Japan, North America, and other segments, employing approximately 3,098 consolidated staff as of September 2025. Recent developments include a co-promotion agreement with Novo Nordisk Pharma Ltd. in October 2025 for Wegovy, a GLP-1 receptor agonist for obesity treatment in Japan, building on their July 2025 Ozempic co-promotion for type 2 diabetes; a March 2025 share purchase agreement with Marubeni Corporation to transfer its Asian pharmaceutical sales business excluding Japan via a company split, with Marubeni acquiring 60% for approximately 45 billion yen and an option for the remainder post-2029; and an April 2025 completion of the sale of subsidiaries Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. to Marubeni Global Pharma Corp. as part of ongoing restructuring; alongside advancements such as submission in August 2025 of a manufacturing and marketing authorization application for allogeneic iPS cell-derived dopaminergic neural progenitor cells in Japan, completion of the CRAFT regenerative medicine manufacturing facility, organizational realignments, and selection of its novel TLR7 vaccine adjuvant for the CEPI library.